Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2015-10-20 Environmental & Social …
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec and Beyond Batten Disease Foundation collaborate to advance emerging therapies to fight juvenile Batten Disease
Environmental & Social Information Classification · 99% confidence The document is a press release dated October 20, 2015, announcing a collaboration (alliance) between Evotec AG and Beyond Batten Disease Foundation regarding drug discovery for Batten disease. It contains standard press release elements like a headline, date, company boilerplate, contact information, and forward-looking statements. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding a partnership. Since there is no specific category for 'Partnership Announcement' or 'Press Release', and it is not a financial report, management change, or shareholder vote result, the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a general category for non-standard corporate news disseminated via news services like DGAP.
2015-10-20 English
Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center
Regulatory Filings Classification · 100% confidence The document is a press release dated October 5, 2015, announcing a multi-year contract award from the U.S. National Cancer Institute (NCI) to Evotec AG. It details the nature of the agreement (compound management services) and its financial value. This type of announcement, which details a significant business development, partnership, or contract win, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate governance filings (like DEF 14A, DVA). It is a general corporate news item disseminated via DGAP. Since it is not a report itself, but a news announcement, and it doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2015-10-05 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1371 chars) titled 'Total Voting Rights Announcement' and references Article 26a of the WpHG. It explicitly states the total number of voting rights as of a specific date (30 September 2015) and mentions an increase due to stock option exercise. This content directly relates to the official results of shareholder voting rights or changes therein, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). It is not a full report, an earnings release, or a management change notice.
2015-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2015
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Voting Rights Announcements' in the header and details a notification regarding a shareholder's voting rights crossing a specific threshold (3.01%) according to Article 21, Section 1 of the WpHG (German Securities Trading Act). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'.
2015-09-28 English
Evotec AG increases its revenue guidance for 2015
Earnings Release Classification · 100% confidence The document is a press release dated September 15, 2015, announcing that Evotec AG is increasing its revenue guidance for 2015. It contains key financial highlights (revenue increase percentage, expected EBITDA, R&D expenses, liquidity forecast) but is not the full, comprehensive annual report (10-K) or a detailed interim report (IR). It is an initial announcement of updated financial expectations, which aligns best with the definition of an Earnings Release (ER), even though it's a guidance update rather than historical results. It is short and serves as an immediate market communication. FY 2015
2015-09-15 English
Evotec AG increases its revenue guidance for 2015
Earnings Release Classification · 100% confidence The document is titled 'News Details' and is classified as 'Ad-hoc' with a date of 15 September 2015. The core content announces that Evotec AG is increasing its financial guidance for 2015, specifically raising the expected revenue growth percentage. This type of announcement, which provides preliminary or updated financial outlook information outside of a formal quarterly or annual report, aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial results and key highlights. Although it's a guidance update rather than a final result, it serves the same function of communicating key financial performance expectations to the market. It is too specific for the general 'RNS' fallback and does not fit other categories like CT, IP, or MDA. FY 2015
2015-09-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.